BAUSCH-Health

News Releases Register for email alerts. All Categories **Archive** Date 12/28/15 **Title** Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence **Download PDF** 12/16/15 **Date Title** Valeant Provides Financial Guidance Update **Download PDF** 12/15/15 **Date Title** Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies **Download** PDF 11/20/15 **Date Title** Valeant To Hold Investor Day On December 16 (Updated) Download **PDF** Date 11/12/15

Title Valeant Pharmaceuticals To Present At Industry Conference **Download PDF** 11/09/15 **Date Title** Valeant To Hold Conference Call For Investors To Provide Business Update Download **PDF** 11/06/15 **Date Title** Valeant Issues Statement On Sales Of Company Stock **Download** PDF 10/30/15 **Date Title** Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee Download **PDF** Date 10/30/15 **Title** Valeant To Terminate Relationship With Philidor **Download PDF** 10/26/15 **Date Title** Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals **Download PDF** 10/26/15 **Date Title** Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor

Download	PDF
Date	10/26/15
Title	
Valeant Pharmaceutic	als Announces The Addition Of G. Mason Morfit To Its Board Of Directors
Download	PDF
Date	10/22/15
Title	
Valeant Pharmaceutic	als To Hold Investor Conference Call On October 26, 2015
Download	PDF
Date	10/21/15
Title	
Valeant Pharmaceutic	als Responds To Erroneous Report
Download	PDF
Date	10/19/15
Title	
Valeant Pharmaceutic	als Reports Third Quarter 2015 Financial Results
Download	PDF
Date	10/15/15
Title	
Valeant Pharmaceutic	als International, Inc. Completes Acquisition Of Synergetics USA, Inc.
Download	PDF
Date	10/15/15
Title	
Valeant Pharmaceutic	als International, Inc. Completes Tender Offer For Synergetics USA, Inc.
Download	PDF
Date	10/14/15
	Page

Title Valeant Provides Update Re	garding Government Inquiries
Download	PDF
Date	10/13/15
Title	
Valeant Pharmaceuticals Ce Bausch + Lomb's Greenville	lebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Solutions Plant
Download	PDF
Date	10/05/15
Title	
Valeant Pharmaceuticals To	Announce 2015 Third Quarter Results On October 19, 2015
Download	PDF
Date	10/05/15
Title	
Valeant Pharmaceuticals An Acquisition Of Synergetics U	nounces Receipt Of Antitrust Clearance For Its Previously Announced JSA, Inc.
Download	PDF
Date	09/22/15
Title	
Bausch + Lomb and Nicox A Candidate VESNEO™ (latane	nnounce FDA Acceptance of New Drug Application for Novel Glaucoma oprostene bunod)
Download	PDF
Date	09/08/15
Title	
Valeant And Progenics Anno	ounce FDA Acceptance Of NDA Submission For Oral RELISTOR®
Download	PDF
Date	09/02/15

Title Valeant Pharmaceuticals	s To Acquire Synergetics USA
Download	PDF
Date	09/01/15
Title	
Valeant And AstraZenec	a To Partner On Brodalumab
Download	PDF
Date	08/25/15
Title	
Valeant Pharmaceutical	s Announces The Addition Of D. Robert Hale To Its Board Of Directors
Download	PDF
Date	08/20/15
Title	
Valeant Pharmaceuticals	s To Acquire Sprout Pharmaceuticals
Download	PDF
Date	07/23/15
Title	
Valeant Pharmaceuticals	s Reports Second Quarter 2015 Financial Results
Download	PDF
Date	07/17/15
Title	
Valeant Pharmaceuticals	s Agrees To Acquire Amoun Pharmaceutical
Download	PDF
Date	06/24/15
Title Valeant Pharmaceuticals	s To Announce 2015 Second Quarter Results On July 23, 2015

Download	PDF
Date	06/23/15
Title	
Valeant and Progenics Annou	unce the Submission of U.S. New Drug Application for Oral RELISTOR®
Download	PDF
Date	06/11/15
Title	
Valeant Pharmaceuticals To A	Appoint Robert L. Rosiello As Chief Financial Officer
Download	PDF
Date	05/27/15
Title	
Salix Announces FDA Approv Syndrome with Diarrhea)	al of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel
Download	PDF
Date	05/19/15
Title	
Valeant Pharmaceuticals Ann	nounces 2015 Annual Meeting Results
Download	PDF
Date	05/12/15
Title	
Valeant Pharmaceuticals To V	Vebcast 2015 Annual Meeting Of Shareholders
Download	PDF
Date	04/29/15
Title	
Valeant Pharmaceuticals Rep	oorts First Quarter 2015 Financial Results (PDF Version)
Download	PDF

Date	04/29/15
Title	
Valeant Pharmaceuticals	Reports First Quarter 2015 Financial Results
Download	PDF
Date	04/29/15
Title	
Valeant Announces CFO	Succession Plan And Additional Executive Appointment
Download	PDF
Date	04/24/15
Title	
	itive CHMP Opinion in the EU for the Treatment of Opioid-Induced
Constipation in Adults Wi	th Chronic Non-Cancer Pain
Download	PDF
Date	04/09/15
	04/09/13
Title	To Announce 2015 First Quarter Desults On April 20, 2015
	To Announce 2015 First Quarter Results On April 29, 2015
Download	PDF
Date	04/01/15
Title Salix Provides Notice of Fi	undamental Changes, Make-Whole Fundamental Changes and Merger
	% Convertible Senior Notes Due 2015
Download	PDF
Date	04/01/15
Title	
	undamental Changes, Make-Whole Fundamental Changes and Merger Convertible Senior Notes Due 2019
Download	PDF
Date	04/01/15
	Page 7 o

Title Redemption of All of Sali:	x's Outstanding 6.00% Senior Notes due 2021
Download	PDF
Date	04/01/15
Title Valeant Pharmaceuticals	International, Inc. Completes Acquisition Of Salix Pharmaceuticals
Download	PDF
Date	04/01/15
Title	
	International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd.
Download	PDF Control of the co
Date	03/27/15
Title	
Valeant Pharmaceuticals	Closes Offering Of \$1.45 Billion Of Common Shares
Download	PDF
Date	03/17/15
Title	
Valeant Pharmaceuticals	Prices Offering Of \$1.45 Billion Of Common Shares
Download	PDF
Date	03/16/15
Title	
Valeant Pharmaceuticals	Announces Offering Of \$1.45 Billion Of Common Shares
Download	PDF
Date	03/16/15
Title	
Valeant And Salix Agree (On Amended Terms To Merger Agreement

Download	PDF
Date	03/13/15
Title	
Valeant Announces HSR Cleara	ance For Salix Acquisition
Download	PDF
Date	03/13/15
Title	
Valeant Announces Pricing Of	Private Offering Of Senior Notes
Download	PDF
Date	03/11/15
Title	
Valeant Comments On Endo C	Offer To Acquire Salix
Download	PDF
Date	03/09/15
Title	
Valeant Annaumass Launah Of	Drivets Official Of Carlies Nata
valeant Announces Launch Of	Private Offering Of Senior Notes
Download	PDF
Download	PDF
Download Date Title	PDF 02/25/15 monstrates Sustained Immune Response Two Years after Treatment in
Download Date Title PROVENGE® (sipuleucel-T) De	PDF 02/25/15 monstrates Sustained Immune Response Two Years after Treatment in
Download Date Title PROVENGE® (sipuleucel-T) De Biochemically-Recurrent Prost	PDF 02/25/15 monstrates Sustained Immune Response Two Years after Treatment in tate Cancer
Download Date Title PROVENGE® (sipuleucel-T) De Biochemically-Recurrent Prost	PDF 02/25/15 monstrates Sustained Immune Response Two Years after Treatment in rate Cancer PDF
Download Date Title PROVENGE® (sipuleucel-T) De Biochemically-Recurrent Prost Download Date Title	PDF 02/25/15 monstrates Sustained Immune Response Two Years after Treatment in rate Cancer PDF
Download Date Title PROVENGE® (sipuleucel-T) De Biochemically-Recurrent Prost Download Date Title	02/25/15 monstrates Sustained Immune Response Two Years after Treatment in tate Cancer PDF 02/22/15

02/22/15 **Date Title** Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results **Download PDF** 02/10/15 **Date Title** Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon **Download PDF Date** 02/05/15 Title Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Download PDF 02/05/15 Date **Title** Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015 Download **PDF** 01/29/15 **Date** Title Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) **Download PDF** 01/20/15 **Date Title** Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform **Download PDF**

01/15/15 **Date Title** Valeant Announces Redemption of All of the Approximately \$500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 **Download PDF** 01/15/15 **Date Title** Valeant Announces Pricing Of Private Offering Of Senior Notes **Download PDF** 01/15/15 **Date** Title Valeant Announces Launch of Private Offering of Senior Notes **Download PDF Date** 01/06/15 **Title** Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference **Download PDF**



LEGAL NOTICE PRIVACY POLICY Investor Inquiries

<u>ir@bauschhealth.com</u>
877-281-6642 **EMAIL ALERTS EMAIL PAGE RSS FEED**

514-856-3855 (Canada)

Media inquiries

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

<u>Corporate.communications@bauschhealth.com</u> 908-569-3692

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

